Dirksen A, Madsen F, Engel T, Frølund L, Heinig J H, Mosbech H
Medical Department, State University Hospital, Copenhagen, Denmark.
Thorax. 1992 Sep;47(9):702-6. doi: 10.1136/thx.47.9.702.
The relation between airway responsiveness to constrictor agents and forced expiratory volume in one second (FEV1) is important when interpreting change in airway responsiveness after an intervention. The aim of the study was to analyse the relation between FEV1 as a percentage of predicted values (% predicted) and airway responsiveness between and within asthmatic subjects.
Results of non-specific bronchial challenge tests were pooled from two randomised crossover studies comparing the effect of a non-sedative antihistamine with placebo in 35 patients with moderate asthma. The design of the two studies was similar: the provocative concentration of either histamine (first study) or methacholine (second study) resulting in a 20% decrease in ventilatory capacity (PC20) was repeated at two week intervals while patients were treated with the antihistamine or placebo. The dose of inhaled corticosteroid was gradually reduced during the study. Data were analysed with PC20 as the dependent variable in a general linear model so that the influence on PC20 of inhaled corticosteroid dose, antihistamine, and choice of bronchoconstricting agent could be separated from the influence of FEV1% predicted.
The correlation coefficient between mean PC20 and mean prechallenge FEV1 for each patient was 0.45. In the general linear model two thirds (65%) of the variation in PC20 was due to variation between subjects. One third of the within subject variation in PC20 could be explained by variation in prechallenge FEV1% predicted (a change in FEV1 of 27% predicted was associated with one doubling or halving of PC20). Treatment with the antihistamine had no influence on PC20, except when histamine was used as the bronchoconstricting agent. The dose of inhaled corticosteroid had a small but significant effect.
The variation in a patient's PC20 over time (several months) is related to changes in FEV1% predicted. Variation in FEV1% predicted explains less of the variation in bronchial responsiveness between subjects where a patient specific factor, which is probably related to the pathogenesis of bronchial asthma, seems to dominate.
在解释干预后气道反应性的变化时,气道对收缩剂的反应性与一秒用力呼气容积(FEV1)之间的关系很重要。本研究的目的是分析哮喘患者之间以及患者自身FEV1占预测值的百分比(%预测值)与气道反应性之间的关系。
两项随机交叉研究的非特异性支气管激发试验结果被汇总,这两项研究比较了一种非镇静性抗组胺药与安慰剂对35例中度哮喘患者的效果。两项研究的设计相似:在患者接受抗组胺药或安慰剂治疗期间,每隔两周重复测定导致通气量下降20%(PC20)的组胺(第一项研究)或乙酰甲胆碱(第二项研究)的激发浓度。在研究过程中,吸入性糖皮质激素的剂量逐渐减少。在一般线性模型中,以PC20作为因变量进行数据分析,以便将吸入性糖皮质激素剂量、抗组胺药和支气管收缩剂的选择对PC20的影响与FEV1%预测值的影响区分开来。
每位患者的平均PC20与激发前平均FEV1之间的相关系数为0.45。在一般线性模型中,PC20变异的三分之二(65%)是由于个体间变异。PC20个体内变异的三分之一可以用激发前FEV1%预测值的变异来解释(FEV1预测值变化27%与PC20加倍或减半相关)。除了使用组胺作为支气管收缩剂时,抗组胺药治疗对PC20没有影响。吸入性糖皮质激素的剂量有小但显著的作用。
患者PC20随时间(几个月)的变化与FEV1%预测值的变化有关。FEV1%预测值的变异对个体间支气管反应性变异的解释较少,一种可能与支气管哮喘发病机制相关的个体特异性因素似乎起主导作用。